017 – Utility of CXCL-8,-10,-13 and CCL-2 chemokines in patients with isolated optic neuritis or transverse myelitis

18 Lug 2019
12:40 - 12:50
Auditorium
NEUROLOGY, POSTER

017 – Utility of CXCL-8,-10,-13 and CCL-2 chemokines in patients with isolated optic neuritis or transverse myelitis

Hana Nohejlova (1, 2) – Jana Kayserova (3) – Zuzana Liba (1)
Department of Paediatric Neurology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital (1) – Department of Neurology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital (2) – Department of Immunology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital (3)


Background:
Optic neuritis (ON) and transverse myelitis (TM) are common symptoms of acquired demyelinating syndromes in childhood with a risk for recurrence. Both can occur in isolation or they are presenting features of acute disseminated encephalomyelitis, multiple sclerosis and neuromyelitis optica spectrum disorders. Pathogenesis of isolated ON and TM remains unclear, suggesting an immune basis. The recognition of neuroinflammation in these cases is challenging. New biomarkers for neuroinflammation, such as chemokines that ensure immune cells migration and interaction at the site of inflammation, are tested.
Objectives:
To determine the clinical utility of four selected C-C and C-X-C motif ligand chemokines in recognition of neuroinflammation in isolated cases of ON and TM.
Methods:
Patients who met the diagnostic criteria for isolated TM (n=7, 29% of females, median age 13 years, range 4-15) or ON (n=15, 80% of females, median age 11 years, range 5-17) and controls (n=15, 60% of females, median age 14 years, range 4-17) were included in the study. Luminex multiple bead technology and software were used to determine the levels of CXCL-8, -10, -13 and CCL-2 in cerebrospinal fluid (CSF) and sera. Nonparametric test were used; p < 0.05 was considered statistically significant.
Results:
In CSF, patients with TM showed increased levels of CXCL-8, -13 and CCL-2, while patients with ON showed only increased level of CXCL-8 in comparison to controls. CSF levels of CXCL-8 and CCL-2 in patients with TM were higher than in patients with ON. In contrast, patients with TM had decreased serum level of CXCL-10, while patients with ON had in serum increased levels of CXCL-8 and -10 in comparison to controls. Serum levels of CXCL-8, -10 and CCL-2 were significantly higher in patients with ON than in patients with TM.
Conclusion:
We observed significant differences in chemokine levels in CSF, but also in sera of the patients in comparison to controls that have a diagnostic potential. In addition, differences between CSF and serum chemokine levels in patients with isolated TM and ON suggest different chemokine involvement and pathogenesis of these two conditions.

Support: This work received support from GAUK (Charles University Grant Agency), Grant No. 914218